Drug intelligence / Profile preview

d-cycloserine + fludrocortisone

Development stage: Preclinical
Lead developer: Streptomyces orchidaceus (original natural source)
Modality: Small Molecules
Administration: Oral

Overview

D-cycloserine + fludrocortisone is a combination of two medications with different mechanisms of action. D-cycloserine is a partial agonist at the glycine recognition site of the glutamatergic NMDA receptor and also functions as a broad-spectrum antibiotic. Fludrocortisone is a synthetic mineralocorticoid used to treat adrenocortical insufficiency and salt-losing adrenogenital syndrome. This combination has been studied for the management of depression.

Targets

MR (Mineralocorticoid receptor)GRIN1 (NMDA receptor subunit 1)

Beyond the preview

Go deeper on d-cycloserine + fludrocortisone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on d-cycloserine + fludrocortisone.

Explore the full profile